Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review
| العنوان: | Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review |
|---|---|
| المؤلفون: | Marius J. van der Mooren, Majoie Hemelaar, Peter Kenemans, Cornelis Kluft, Mandana Rad |
| المساهمون: | TNO Kwaliteit van Leven, Obstetrics and gynaecology, ICaR - Ischemia and repair |
| المصدر: | Fertility and Sterility, 3, 90, 642-672 Hemelaar, M, van der Mooren, M J, Rad, M, Kluft, C & Kenemans, P 2008, ' Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review ', Fertility and Sterility, vol. 90, no. 3, pp. 642-672 . https://doi.org/10.1016/j.fertnstert.2007.07.1298 Fertility and Sterility, 90(3), 642-672. Elsevier Inc. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Homocysteine, medicine.medical_treatment, Administration, Oral, protein C, Protein S, endothelial dysfunction, chemistry.chemical_compound, systematic review, cardiovascular disease, Risk Factors, Postmenopausal hormone therapy, Endothelial dysfunction, conjugated estrogen, Venous Thrombosis, medroxyprogesterone acetate, C reactive protein, hormonal therapy, biology, intranasal, chlormadinone acetate, medrogestone, Incidence, lipoprotein, drug effect, Estrogen Replacement Therapy, article, Obstetrics and Gynecology, clinical trial, cyproterone acetate plus estradiol valerate, antithrombin, postmenopause, blood clotting factor 7, n(g),n(g) dimethylarginine, priority journal, fibrinolysis, Biological Markers, Female, dydrogesterone plus estradiol, protein S, cardiovascular risk, medicine.medical_specialty, norethisterone acetate, venous thromboembolism, hormone, progesterone, blood clotting, Risk Assessment, Internal medicine, estradiol, Fibrinolysis, medicine, estrone sulfate, drug mechanism, follow up, Humans, endothelin 1, human, Risk factor, Biology, outcome assessment, prothrombin, gestodene, business.industry, Vascular disease, C-reactive protein, activated protein C, Estrogens, homocysteine, medicine.disease, Atherosclerosis, dydrogesterone, ischemic heart disease, nomegestrol acetate, Endocrinology, estradiol valerate, Reproductive Medicine, chemistry, inflammation, transdermal, biology.protein, placebo, Hormone therapy, business, cell adhesion molecule, Biomarkers |
| الوصف: | Objective: To review the effects of non-oral administration of postmenopausal hormone therapy (HT) on risk markers for atherosclerotic and venous thromboembolic disease.Non-oral postmenopausal HT appears not to increase venous thromboembolic risk, whereas the effect on coronary heart disease risk is less clear. Design: Systematic review of literature obtained from MEDLINE, EMBASE, and CENTRAL databases from 1980 until and including April 2006. Terms for "postmenopausal hormone therapy" and for "non-oral administration" were combined in the search. Setting: Randomized clinical trials. Patient(s): Postmenopausal women, both healthy and with established cardiovascular disease or specified cardiovascular risk factors. Intervention(s): Non-oral HT (e.g., transdermal or intranasal) compared with oral HT or no treatment/placebo. Main Outcome Measure(s): Lipoprotein(a), homocysteine, C-reactive protein (CRP), cell adhesion molecules, markers of endothelial dysfunction, coagulation, and fibrinolysis. Result(s): Seventy-two studies investigating either transdermal or intranasal administration were included. For non-oral HT, decreases in lipoprotein(a), cell adhesion molecules, and factor VII generally were significant, resistance to activated protein C (APCr) was slightly increased, and other markers including CRP and homocysteine did not change. Compared with oral HT, changes in CRP and APCr were smaller, changes in cell adhesion molecules and some fibrinolytic parameters tended to be smaller, whereas changes in other factors including lipoprotein(a) and homocysteine did not differ. Conclusion(s): Potentially unfavorable changes seen with oral HT on two important markers, CRP and APCr, are substantially smaller with non-oral HT. Non-oral HT has minor effects on the other cardiovascular risk markers studied. Therefore, compared with oral HT, non-oral HT appears be safer with respect to atherosclerotic and venous thromboembolic disease risk. © 2008 American Society for Reproductive Medicine. |
| اللغة: | English |
| تدمد: | 0015-0282 |
| DOI: | 10.1016/j.fertnstert.2007.07.1298 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0048a3060cd79e9ba05d7d23800a97e http://resolver.tudelft.nl/uuid:7994f620-bb3b-4383-ac78-b4885b4074fe |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f0048a3060cd79e9ba05d7d23800a97e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00150282 |
|---|---|
| DOI: | 10.1016/j.fertnstert.2007.07.1298 |